Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
AssigneeSignal Pharmaceuticals, LLC
InventorsHon-Wah Man, Jean Xu, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou, Ying Li, Lianfeng Huang, Daozhong Zou
Life of this patent
Estimating the term…
Abstract
Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
Claims32
1-20. (canceled)
A method for treating a condition treatable by inhibition of a kinase pathway, comprising administering to a subject having a condition treatable by inhibition of a kinase pathway an effective amount of a crystal form of Compound 1, or a tautomer thereof:
A method for treating interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus, comprising administering to a subject having interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus an effective amount of a crystal of comprising Compound 1, or a tautomer thereof:
A method for treating a liver fibrotic disorder, diabetes, metabolic syndrome leading to a liver fibrotic disorder, or a condition treatable by inhibition of a kinase pathway, comprising administering to a subject having a liver fibrotic disorder, diabetes, metabolic syndrome leading to a liver fibrotic disorder, or a condition treatable by inhibition of a kinase pathway an effective amount a crystal form of Compound 1, or a tautomer thereof:
Dependencies are inferred from the claim text.